<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">actabiomedica</journal-id><journal-title-group><journal-title xml:lang="ru">Acta Biomedica Scientifica</journal-title><trans-title-group xml:lang="en"><trans-title>Acta Biomedica Scientifica</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2541-9420</issn><issn pub-type="epub">2587-9596</issn><publisher><publisher-name>Scientific Centre for Family Health and Human Reproduction Problems</publisher-name></publisher></journal-meta><article-meta><article-id custom-type="elpub" pub-id-type="custom">actabiomedica-951</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОБЗОРЫ ЛИТЕРАТУРЫ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>REVIEWS OF LITERATURE</subject></subj-group></article-categories><title-group><article-title>ОПРЕДЕЛЕНИЕ СОДЕРЖАНИЯ ЦИТОКИНОВ В РЕШЕНИИ ОСНОВНЫХ КЛИНИЧЕСКИХ ЗАДАЧ</article-title><trans-title-group xml:lang="en"><trans-title>DEFINING CYTOKINES CONTENTS IN SOLVING MAIN CUNICAL ISSUES</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ширинский</surname><given-names>В. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Shirinskiy</surname><given-names>V. S.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ширинский</surname><given-names>И. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Shirinskiy</surname><given-names>I. V.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>НИИ клинической иммунологии СО РАМН</institution></aff><aff xml:lang="en"><institution>Research Institute of Clinical Immunology SB RAMS</institution></aff></aff-alternatives><pub-date pub-type="collection"><year>2012</year></pub-date><pub-date pub-type="epub"><day>28</day><month>05</month><year>2012</year></pub-date><volume>0</volume><issue>3(2)</issue><fpage>355</fpage><lpage>357</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Ширинский В.С., Ширинский И.В., 2012</copyright-statement><copyright-year>2012</copyright-year><copyright-holder xml:lang="ru">Ширинский В.С., Ширинский И.В.</copyright-holder><copyright-holder xml:lang="en">Shirinskiy V.S., Shirinskiy I.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.actabiomedica.ru/jour/article/view/951">https://www.actabiomedica.ru/jour/article/view/951</self-uri><abstract><p>Достижения в понимании биологии цитокинов, их роли в развитии различных заболеваний, успехи анти-цитокиновой терапии привели к предположению, что цитокины можно использовать в качестве биомаркеров для решения разнообразных клинических задач. Целью этого обзора является обобщение данных литературы и результатов собственных исследований, касающихся использования цитокинов в качестве биомаркеров для оценки «бремени» болезни, прогноза заболевания, постановки, диагноза и предсказания ответа на лечение.</p></abstract><trans-abstract xml:lang="en"><p>Breakthroughs in cytokine biology, appraisal of their importance in many diseases, and successes of anticytokine therapy have lead to an assumption that cytokines can be used as biomarkers in various clinical settings. The aim of this review is to discuss some data from the literature and our own data pertaining to the use of cytokines as biomarkers for the assessment of disease burden, prognosis, diagnosis, and prediction of response to treatment.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>биомаркеры</kwd><kwd>цитокины</kwd></kwd-group><kwd-group xml:lang="en"><kwd>biomarkers</kwd><kwd>cytokines</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Хэгглин Р. Дифференциальная диагностика внутренних болезней. — М.: Инженер, 1993. — 794 с.</mixed-citation><mixed-citation xml:lang="en">Хэгглин Р. Дифференциальная диагностика внутренних болезней. — М.: Инженер, 1993. — 794 с.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Ширинский И.В., Желтова О.И., Соловьева Н.Ю., Ширинский В.С. и др. Эффективность и безопасность симвастатина при ревматоидном артрите: открытое контролируемое исследование // Мед. иммунология. — 2007. — № 4 — 5. — С. 477 — 482.</mixed-citation><mixed-citation xml:lang="en">Ширинский И.В., Желтова О.И., Соловьева Н.Ю., Ширинский В.С. и др. Эффективность и безопасность симвастатина при ревматоидном артрите: открытое контролируемое исследование // Мед. иммунология. — 2007. — № 4 — 5. — С. 477 — 482.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Bauer D.C., Hunter D.J., Abramson S.B., Attur M. et al. Classification of osteoarthritis biomarkers: a proposed approach // Osteoarthritis Cartilage. — 2006. — Vol. 14. — P. 723 — 727.</mixed-citation><mixed-citation xml:lang="en">Bauer D.C., Hunter D.J., Abramson S.B., Attur M. et al. Classification of osteoarthritis biomarkers: a proposed approach // Osteoarthritis Cartilage. — 2006. — Vol. 14. — P. 723 — 727.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Bozza F.A., Salluh J.I., Japiassu A.M., Soares M. et al. Cytokine profiles as markers of disease severity in sepsis: a multiplex analysis // Crit Care. — 2007. — Vol. 11. — P. 49.</mixed-citation><mixed-citation xml:lang="en">Bozza F.A., Salluh J.I., Japiassu A.M., Soares M. et al. Cytokine profiles as markers of disease severity in sepsis: a multiplex analysis // Crit Care. — 2007. — Vol. 11. — P. 49.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Danesh J., Kaptoge S., Mann A.G., Sarwar N. et al. Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review // PLoS Med. — 2008. — Vol. 5. — P. 78.</mixed-citation><mixed-citation xml:lang="en">Danesh J., Kaptoge S., Mann A.G., Sarwar N. et al. Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review // PLoS Med. — 2008. — Vol. 5. — P. 78.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Gattorno M., Federici S., Pelagatti M.A., Caorsi R. et al. Diagnosis and management of autoinflammatory diseases in childhood // J. Clin. Immunol. — 2008. — Vol. 28. — Suppl. 1. — P. 73 — 83.</mixed-citation><mixed-citation xml:lang="en">Gattorno M., Federici S., Pelagatti M.A., Caorsi R. et al. Diagnosis and management of autoinflammatory diseases in childhood // J. Clin. Immunol. — 2008. — Vol. 28. — Suppl. 1. — P. 73 — 83.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Rho Y.H., Chung C.P., Oeser A., Solus J. et al. Inflammatory mediators and premature coronary atherosclerosis in rheumatoid arthritis // Arthritis Rheum. — 2009. — Vol. 61. — P. 1580—1585.</mixed-citation><mixed-citation xml:lang="en">Rho Y.H., Chung C.P., Oeser A., Solus J. et al. Inflammatory mediators and premature coronary atherosclerosis in rheumatoid arthritis // Arthritis Rheum. — 2009. — Vol. 61. — P. 1580—1585.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Rooney T., Roux-Lombard P., Veale D.J., FitzGerald O. et al. Synovial tissue and serum biomarkers of disease activity, therapeutic response and radiographic progression: analysis of a proof-of-concept randomised clinical trial of cytokine blockade // Ann. Rheum. Dis. — 2010. — Vol. 69. — P. 706 — 714.</mixed-citation><mixed-citation xml:lang="en">Rooney T., Roux-Lombard P., Veale D.J., FitzGerald O. et al. Synovial tissue and serum biomarkers of disease activity, therapeutic response and radiographic progression: analysis of a proof-of-concept randomised clinical trial of cytokine blockade // Ann. Rheum. Dis. — 2010. — Vol. 69. — P. 706 — 714.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Sahab Z.J., Semaan S.M., Sang Q.X. Methodology and applications of disease biomarker identification in human serum // Biomark Insights. — 2007. — Vol. 2. — P. 21—43.</mixed-citation><mixed-citation xml:lang="en">Sahab Z.J., Semaan S.M., Sang Q.X. Methodology and applications of disease biomarker identification in human serum // Biomark Insights. — 2007. — Vol. 2. — P. 21—43.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Shirinsky I.V., Zheltova O.I., Solovyova N.Y., Kozlov V.A. et al. Changes in disease activity, cytokine production, and proliferation of peripheral blood mononuclear cells in patients with rheumatoid arthritis after simvastatin treatment // Scand. J. Rheumatol. — 2009. — Vol. 38. — P. 23 — 27.</mixed-citation><mixed-citation xml:lang="en">Shirinsky I.V., Zheltova O.I., Solovyova N.Y., Kozlov V.A. et al. Changes in disease activity, cytokine production, and proliferation of peripheral blood mononuclear cells in patients with rheumatoid arthritis after simvastatin treatment // Scand. J. Rheumatol. — 2009. — Vol. 38. — P. 23 — 27.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Syversen S.W., Landewe R., van der Heijde D., Bathon J.M. et al. Testing of the OMERACT 8 draft validation criteria for a soluble biomarker reflecting structural damage in rheumatoid arthritis: a systematic literature search on 5 candidate biomarkers // J. Rheumatol. — 2009. — Vol. 36. — P. 1769 — 1784.</mixed-citation><mixed-citation xml:lang="en">Syversen S.W., Landewe R., van der Heijde D., Bathon J.M. et al. Testing of the OMERACT 8 draft validation criteria for a soluble biomarker reflecting structural damage in rheumatoid arthritis: a systematic literature search on 5 candidate biomarkers // J. Rheumatol. — 2009. — Vol. 36. — P. 1769 — 1784.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Fletcher R.H., Fletcher S.W. Clinical Epidemiology. The Essentials, 4th ed. — Baltimore: Lipincott Williams and Wilkins, 2005. — 288 p.</mixed-citation><mixed-citation xml:lang="en">Fletcher R.H., Fletcher S.W. Clinical Epidemiology. The Essentials, 4th ed. — Baltimore: Lipincott Williams and Wilkins, 2005. — 288 p.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
